Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Chronic myelogenous leukemia

Activity of venetoclax-based therapy in chronic myelomonocytic leukemia

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Mutation landscape and dynamics, and clinical outcomes of study population.

Data availability

The datasets generated during and/or analyzed during the current study are not publicly available due to patient privacy concerns but are available from the corresponding author on reasonable request.

References

  1. 1.

    Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

    CAS  Article  Google Scholar 

  2. 2.

    Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.

    CAS  Article  Google Scholar 

  3. 3.

    Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002;99:840–9.

    CAS  Article  Google Scholar 

  4. 4.

    Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31:2428–36.

    CAS  Article  Google Scholar 

  5. 5.

    Alfonso A, Montalban-Bravo G, Takahashi K, Jabbour EJ, Kadia T, Ravandi F, et al. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol. 2017;92:599–606.

    CAS  Article  Google Scholar 

  6. 6.

    Ganan-Gomez I, Alfonso A, Yang H, Santoni A, Marchica V, Fiorini E, et al. Cell-type specific mechanisms of hematopoietic stem cell (HSC) expansion underpin progressive disease in myelodysplastic syndromes (MDS) and provide a rationale for targeted therapies. Blood. 2018;132:1798.

    Article  Google Scholar 

  7. 7.

    Wei AH, Garcia JS, Borate U, Fong CY, Baer MR, Nolte F, et al. A phase 1b study evaluating the safety and efficacy of venetoclax in combination with azacitidine in treatment-naïve patients with higher-risk myelodysplastic syndrome. Blood. 2019;134:568.

    Article  Google Scholar 

  8. 8.

    Zeidan AM, Pollyea DA, Garcia JS, Brunner A, Roncolato F, Borate U, et al. A phase 1b study evaluating the safety and efficacy of venetoclax as monotherapy or in combination with azacitidine for the treatment of relapsed/refractory myelodysplastic syndrome. Blood. 2019;134:565.

    Article  Google Scholar 

  9. 9.

    DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135:791–803.

    CAS  Article  Google Scholar 

  10. 10.

    Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Disco. 2020;10:536–51.

    CAS  Article  Google Scholar 

  11. 11.

    Savona MR, Malcovati L, Komrokji R, Tiu RV, Mughal TI, Orazi A, et al. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood. 2015;125:1857–65.

    CAS  Article  Google Scholar 

  12. 12.

    Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

    Article  Google Scholar 

  13. 13.

    Kanagal-Shamanna R, Medeiros LJ, Lu G, Wang SA, Manning JT, Lin P, et al. High-grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis. Histopathology. 2012;61:945–54.

    Article  Google Scholar 

  14. 14.

    Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9:351–65.

    CAS  Article  Google Scholar 

  15. 15.

    Teh TC, Nguyen NY, Moujalled DM, Segal D, Pomilio G, Rijal S, et al. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. Leukemia. 2018;32:303–12.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

This work was supported in part by the University of Texas MD Anderson Cancer Center Support Grant CA016672.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Guillermo Montalban-Bravo.

Ethics declarations

Conflict of interest

KS: This author declares an advisory role with Pfizer Japan. EJ: This author declares research support and an advisory role with Adaptive, AbbVie, Amgen, Pfizer, Cyclacel LTD, Takeda, and Bristol Myers Squibb. CD: This author declares research support and an advisory role with Abbvie/Genentech, Agios, Celgene/BMS, ImmuneOnc, Novartis and Notable Labs, and honoraria from Takeda and Foghorn Therapeutics. MK: This author declares research support and an advisory role with Eli Lilly, AbbVie, Cellectis, Amgen, F. Hoffman La-Roche, Genentech, Ascentage, Kisoji, Reata Pharmaceuticals, Ablynx, Astra Zeneca, Agios, Forty-Seven, Stemline Therapeutics, and Calithera. T.K.: This author declares research support and an advisory role with Amgen, Bioline RX, Pfizer, Jazz, Bristol Myers Squibb, Celgene, Genentech, Pharmacyclics, Takeda, and AbbVie. FR: This author declares research support and an advisory role with Macrogeni, Selvita, Cyclacel LTD, Menarini Ricerche, and Xencor. HK: This author declares research support and an advisory role with Actinium, and research support from AbbVie, Agio, Amgen, Ariad, Astex, Bristol Myers Squibb, Cyclacel, Daiichi-Sankyo, Immunogen, Jazz Pharma, Novartis, and Pfizer. GG-M: This author declares research support and an advisory role with Bristol Myers Squibb, Astex, and Helsinn, and research support from Amphivena, Novartis, AbbVie, H3 Biomedicine, Onconova, and Merck. The remaining authors declare no conflicts of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Montalban-Bravo, G., Hammond, D., DiNardo, C.D. et al. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia 35, 1494–1499 (2021). https://doi.org/10.1038/s41375-021-01240-2

Download citation

Search

Quick links